NEWS & MEDIA
We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.
PRESS RELEASES
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
Florham Park, N.J., May 28, 2025 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the...
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism...
BeyondSpring Files 2024 Annual Report on Form 10-K
Florham Park, N.J., March 27, 2025 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the...
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. Docetaxel Plinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in...
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Florham Park, N.J., January 28, 2025 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has entered into definitive agreements to sell...
